Antibacterial Agents TRIZ Cases

Specific bacteriophage strains infect and lyse adherent-invasive E. coli while maintaining the healthy human microbiome.

This case examines triazole antifungal agents as an alternative to antibiotics for resistant Neisseria gonorrhoeae and N. meningitidis infections.

Death-phase EVs induce programmed cell death and oxidative stress to disrupt antibiotic-resistant bacterial biofilms.

Genetic diversity and antibiotic resistance complicate S. aureus vaccines; conserved SpA and LukAB targets enable antibody-driven bacterial clearance.

Combining M23 and CHAP cleavage activities helps lyse Staphylococcus cell walls while preserving stability in human serum.

Spore-former bacteria compete with gut microbes carrying resistance genes, reducing their abundance and disrupting antibiotic resistance transmission.

See how puupehenone derivatives target drug-resistant C. difficile, tuberculosis, and E. faecalis while reducing toxin production and treatment duration.

N-Acetyl-D-amino acids stabilize aqueous Vancomycin solutions, maintaining at least 85% activity and purity for up to 24 months at room temperature.

β-Galactosidase-treated whey inhibits TNF-α and IL-1β production, providing an orally ingestible alternative to conventional anti-inflammatory agents.

F71Y and F144V mutations lock the FimH lectin domain in a low-affinity state to induce antibodies that block E. coli adhesion.

An alcohol-free aqueous-oil lotion replaces antibiotics and metal compounds while reducing S. pseudointermedius by 99.99% in 24 hours.

Recombinant antigens and antibody assays help control GDF-8 release from prodomain complexes for signaling modulation.

Beneficial R. gnavus and L. reuteri stimulate Reg3 and other antimicrobial peptides to counter antibiotic-resistant bacterial colonization.

Replacing selected lysine or arginine residues with histidine in immunoglobulin CDRs helps polypeptides resist intestinal proteases for oral delivery.

Peptide linkers permit one controlled disulfide bond between Fab chains, reducing molecular mismatching and aggregation while extending antibody half-life.

Using 218 SNPs across the hem locus, this case distinguishes acne-associated α-type strains from β-type strains for selective treatment.

New chemical structures target TLR7 activation more strongly than CB-7 and help reduce IL-6 and IFN-α production.

Using 40–74% soy phosphatidylserine with multivalent cations avoids costly purification while forming stable cochleates for drug delivery.

Diazabicyclic compounds inhibit class A, B, C, and D β-lactamases, helping restore β-lactam antibiotic activity against resistant bacteria.

Adding 3-hydroxybutyrate to enteral or parenteral macronutrient feeding targets muscle weakness during critical illness.

Targeted nanoparticles activated by electromagnetic fields disrupt biofilm matrices and improve antimicrobial penetration in persistent infections.

See how a compound inoculum of two probiotic strains inhibits diarrhea-related pathogens while preserving yogurt acidity, texture, flavor, and probiotic activity.

Three domains target peptidoglycan, ester linkages, and membranes in one peptide to disrupt mycobacterial walls and kill latent cells.

Oral 450 mg loading and 300 mg follow-up dosing uses 9-aminomethyl minocycline to treat bacterial skin infections without IV visits.

A detergent–denaturant formulation dissolves wound eschar without enzymatic or sharp debridement, helping limit pain, inflammation, and cost.

Controlled lipid diffusion keeps local anesthetic on open body surfaces for 12–72 hours while limiting high blood concentrations.

Histidine, povidone, and mannitol address incomplete disintegration and poor dissolution in Afabicin solid compositions.

Specific amino acid domains combine MMP and angiogenesis inhibition to limit fibroblast activation and matrix deposition in fibrosis.

Recurrent BV can return after standard therapy; simultaneous vaginal boric acid and nitroimidazole targets pathogens for longer-lasting control.

Combining hydroxyacetophenone with 1,3-propanediol or mastic extract supports broad microbial protection while preserving formulation stability and thickness.

See how anti-AA antibodies bind residues 70–76 on amyloid A fibrils to inhibit deposition and clear existing aggregates.

Carrier-free micronized tigecycline powder targets deep lung infections while reducing systemic dose requirements and reconstitution.

Limited Gram-negative membrane entry is addressed by tuning Ribocil C molecular weight and polarity for porin diffusion.

Purified lyophilized strains reduce S. aureus virulence-gene expression while preserving storage stability for topical skin treatment.

Human monoclonal antibodies bind and neutralize EEEV, enabling infection detection, viral-load reduction, and protection in animal models.

Metal-scavenging treatment removes catalyst residues during compound preparation while targeting activity against resistant Gram-negative bacteria.

Liposomal glycerol monolaurate delivery treats skin and mucosal infections while buffering irritation and supporting patient compliance.

ClbP activates the prodrug only inside colibactin-producing E. coli, selectively killing these strains while preserving gut microbiome balance.

Low Darobactin A yield limits structural engineering and semi-synthesis; substituted derivatives address production and Gram-negative activity.

Lactobacillus reuteri regulates pH and suppresses pathogens while preserving normal flora.

This case uses the CI-1040 metabolite PD-0184264 to reduce viral and bacterial loads with low cytotoxicity.

Heterocyclic compounds target STAT3 while addressing solubility and membrane permeability.

Nanobodies targeting CmeC, CadF, CfrA, CjaD, and flagella enable rapid Campylobacter colonization reduction in poultry.

This case uses engineered TCR variable regions to recognize RLPAKAPLL-HLA-E and support specific T cell responses against TB-infected cells.

P1' functional groups tune Kgp selectivity and pharmacokinetics while reporter probes measure gingipain activity.

Optimized hybrid proteins improve solubility and stability while rapidly lysing drug-resistant Gram-negative bacteria.

ELISA and Western blotting detect antibodies to Ruminococcus gnavus antigens for noninvasive lupus nephritis monitoring.

Humanized IL1RAP antibodies target cancer cells for internalization and IL-1 signaling inhibition.

Depleted harmful components and enriched outer membrane proteins enable aOMVs to support cancer treatment with tumor vesicles.

This case combines MMP, angiogenesis, and integrin inhibition in one polypeptide to reduce fibroblast activation and matrix deposition.